Loading...
•
Jun 30, 2022
Revance Q2 2022 Earnings Report
Reported financial results for the second quarter and provided a corporate update.
Key Takeaways
Revance Therapeutics reported a strong second quarter, with revenue of $28.4 million, a 51% increase from the same period in 2021. The company's RHA® Collection revenue reached $25.5 million, marking its best performing quarter since launch.
PDUFA date of September 8, 2022 for DaxibotulinumtoxinA for Injection in glabellar lines
Reinspection of manufacturing facility completed as part of Class II BLA resubmission for DaxibotulinumtoxinA for Injection in glabellar lines
Second quarter total revenue of $28.4 million, with RHA® Collection revenue of $25.5 million
Aesthetic accounts across products and services totaled over 4,000 at quarter-end
Forward Guidance
Revance expects 2022 GAAP operating expenses to be $375 million to $400 million and non-GAAP operating expenses to be $260 million to $280 million. Revance expects 2022 non-GAAP research and development expense to be $100 million to $110 million. Management projects that the company is funded into 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...